[DGTR tracker](https://indusdesk.com/dgtr/tracker/)

# DGTR opens anti-dumping investigation into amoxycillin trihydrate from China

https://indusdesk.com/dgtr/tracker/opens-anti-dumping-investigation-into-amoxycillin-trihydrate-276715/

The Directorate General of Trade Remedies has initiated an anti-dumping investigation, by notification dated September 24, 2026 (SETU Case ID – AD/OI/060/2026), concerning imports of Amoxycillin Trihydrate originating in or exported from China. The application was filed by Apitoria Pharma Private Limited, a stepdown wholly owned subsidiary of Aurobindo Pharma Ltd., and is supported by Centrient Pharmaceuticals India Private Limited.

SETU Case ID – AD/OI/060/2026 · Initiation · September 24, 2026

IndusDesk · September 24, 2026

The Directorate General of Trade Remedies has initiated an anti-dumping investigation, by notification dated September 24, 2026 (SETU Case ID – AD/OI/060/2026), concerning imports of Amoxycillin Trihydrate originating in or exported from China.

The application was filed by Apitoria Pharma Private Limited, a stepdown wholly owned subsidiary of Aurobindo Pharma Ltd., and is supported by Centrient Pharmaceuticals India Private Limited. The applicant states it accounts for more than 35% of Indian production, and the two together for more than 60%. Amoxicillin is described as a broad-spectrum penicillin antibiotic. The product is classified under sub-heading 29411030, which is indicative only.

The period of investigation is April 1, 2025 to March 31, 2026, and the injury period covers the three financial years from April 1, 2022 to March 31, 2025 and the period of investigation. Normal value for China was constructed from the applicant's cost of production. The Authority finds prima facie evidence of a dumping margin above de minimis, an absolute increase in subject imports and an adverse effect on the domestic industry's profitability.

Interested parties must register on the SETU portal and file questionnaire responses within 37 days from circulation of the non-confidential version of the application. Comments on the product scope and PCN methodology are due within 15 days, running concurrently. The Authority will determine the existence, degree and effect of dumping and recommend any duty needed to remove injury.

**Measure**: Anti-dumping

**Stage**: Initiation

**Case number**: SETU Case ID – AD/OI/060/2026

**File number**: F. No. 6/59/2026-DGTR

**Dated**: September 24, 2026

**Published in the Gazette**: September 24, 2026

**Put online**: October 2, 2026

**Gazette ID**: CG-DL-E-02102026-276715

**Product**: Amoxycillin Trihydrate

**What it covers**: Amoxicillin is a semi-synthetic, broad-spectrum penicillin antibiotic used mainly to treat bacterial infections of the respiratory tract, ear, throat, urinary tract and skin, and dental infections, and in combination with other drugs for H. pylori-related peptic ulcers. The unit of measurement is Metric Tonnes (MT), and the customs classification is indicative only and not binding on the scope.

**Customs codes**: 29411030

**Countries**: China

**Applicant**: Apitoria Pharma Private Limited, supported by Centrient Pharmaceuticals India Private Limited

**Period of investigation**: 1st April 2025 to 31st March 2026 (12 months)

**Injury period**: 1st April 2022 to 31st March 2023, 1st April 2023 to 31st March 2024, 1st April 2024 to 31st March 2025 and the period of investigation

**Findings**:

- The applicant, a stepdown wholly owned subsidiary of Aurobindo Pharma Ltd., states it accounts for more than 35% of Indian production, and with the supporter for more than 60%; the Authority considers it an eligible domestic industry under Rule 2(b) and finds Rule 5(3) satisfied.

- The applicant claims China should be treated as a non-market economy; normal value was constructed on the applicant's cost of production, adjusted for selling, general and administrative expenses, with reasonable profit.

- A comparison of normal value and export price at ex-factory level prima facie shows a dumping margin above the de-minimis level.

- The volume of subject imports has increased in absolute terms and the imports have had an adverse impact on the profitability parameters of the domestic industry.

- The Authority prima facie finds sufficient evidence of dumping, injury and causal link to justify initiation under Rule 5.

**Recommendation**: The Authority initiates an anti-dumping investigation under Section 9A of the Act read with Rule 5 to determine the existence, degree and effect of dumping and to recommend an appropriate amount of anti-dumping duty adequate to remove the injury to the domestic industry.

**Time limits**:

- Comments on the scope of the product under consideration and proposed PCN methodology: within 15 days of circulation of the receipt of intimation of initiation of the investigation, running concurrently with the time limit for submissions

- Questionnaire responses and other submissions, confidential and non-confidential versions, on the SETU portal (case ID AD/OI/060/2026): within 37 days from the date on which the non-confidential version of the application is circulated by the Authority or transmitted to the diplomatic representative of the exporting country

- Requests for extension of time: at least one day before the original deadline

- Comments on issues of confidentiality: within 7 days from the date of circulation of the non-confidential version of the documents

[The notification](https://files.indusdesk.com/dgtr/cases/setu-ad-oi-60-2026/initiation-2026-09-24.pdf) (PDF, 811 KB)

Gazette of India, [CG-DL-E-02102026-276715](https://egazette.gov.in/WriteReadData/2026/276715.pdf), published September 24, 2026.

Checked against the official copy on October 20, 2026.

- [DGTR guide](https://indusdesk.com/dgtr/)

- [All DGTR notifications](https://indusdesk.com/dgtr/tracker/)
